Principal Investigator Western Reserve Academy Hudson, Ohio, United States
Disclosure(s):
Roberto Aguilar, PhD: No financial relationships to disclose
Introduction/Rationale: Glioblastoma multiforme (GBM) is an aggressive and treatment-resistant brain tumor with limited understanding of the regulatory mechanisms that promote tumor persistence. The pseudogene MTRNR2L1 has been reported to be upregulated in several cancers, but its function in glioblastoma remains unknown. This study aims to characterize MTRNR2L1 expression in GBM and determine whether it contributes to tumor cell survival and growth.
Methods: RNA was extracted from U87-MG glioblastoma cells, and MTRNR2L1 expression was confirmed through cDNA synthesis and quantitative PCR. A gene knockout was designed using CRISPR technology, and ongoing experiments are assessing how MTRNR2L1 loss affects cell viability and proliferation compared with wild-type controls.
Results: qPCR analysis confirmed MTRNR2L1 expression in U87-MG glioblastoma cells. Preliminary knockout studies suggest that loss of MTRNR2L1 may reduce glioblastoma cell proliferation and survival. Additional validation is underway to clarify its role in regulating tumor cell behavior.
Conclusion: MTRNR2L1 is a previously uncharacterized pseudogene expressed in glioblastoma that may influence tumor growth and cell survival. Functional characterization of this gene will help clarify its contribution to cancer-associated pseudogene networks and may reveal new targets for future glioblastoma research.
